Tag: chronic kidney disease
-
Finerenone across CKM stages — the relative effect is flat, the absolute benefit is not, and the new endpoint moves its own goalposts
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. A post hoc analysis of 12,990 people with type 2 diabetes and chronic kidney disease from two phase 3 trials, pooled and then re-classified using the…
-
Do incretins move hard outcomes in CKM, not just weight? A close read of SELECT, FLOW and SUMMIT
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. GLP-1 / incretin agents lowered hard cardiovascular (SELECT) and kidney (FLOW) outcomes. In SELECT’s pre-specified analysis, roughly two-thirds of the cardiovascular benefit appeared independent of…
-
Finerenone and the CKM “third pillar” — complementarity is a division of outcomes, and the anti-fibrotic expansion is preclinical-thick but human-empty
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Finerenone completes the cardio-kidney-metabolic (CKM) “three-pillar” standard of care alongside SGLT2 inhibitors and GLP-1 agonists through a non-overlapping anti-inflammatory / anti-fibrotic axis. But the real substance…
-
Does finerenone move hard outcomes, or mainly organ and morbidity endpoints? A close read of FIDELITY, FINEARTS-HF and FINE-HEART
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Finerenone (a non-steroidal mineralocorticoid receptor antagonist) reduced kidney and heart-failure morbidity endpoints consistently across three pooled trial layers. But the single hardest endpoint, cardiovascular death,…
-
The finerenone landscape — a nonsteroidal MRA as the third pillar of CKM care, and what is still an open question
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that targets inflammation and fibrosis rather than blood pressure and volume — a mechanism that does not overlap…
-
Do incretins move hard outcomes in CKM, not just weight? A close read of SELECT, FLOW and SUMMIT
This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record. Read the current version → Whether GLP-1 receptor agonists improve hard cardiovascular and kidney outcomes in cardio-renal-metabolic disease, rather than weight alone — read against the SELECT, FLOW and SUMMIT trials. The…
-
Who names the disease — America’s CKM and Europe’s SMD, two axes of definitional power over metabolic disease
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Two upper-level disease taxonomies are competing over the cardio-renal-metabolic continuum. In the United States, the AHA-led CKM (Cardiovascular-Kidney-Metabolic) Syndrome (2023 advisory → 2026 multisociety guideline).…
Uthando Nethemba 